Gantenerumab Does Not Slow Clinical Decline in Early Alzheimer Disease
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 16, 2023 -- The use of gantenerumab leads to lower amyloid plaque burden at 116 weeks, but is not associated with slower clinical decline among patients with early Alzheimer disease, according to a study published in the Nov. 16 issue of the New England Journal of Medicine.
Randall J. Bateman, M.D., from the Washington University School of Medicine in St. Louis, and colleagues conducted two phase 3 trials involving participants aged 50 to 90 years with mild cognitive impairment or mild dementia due to Alzheimer disease and evidence of amyloid plaques. Overall, 985 and 980 participants in the GRADUATE I and GRADUATE II trials, respectively, were randomly assigned to receive gantenerumab or placebo every two weeks.
The researchers found that the change from baseline in the Clinical Dementia Rating Scale-Sum of Boxes score at week 116 was 3.35 and 3.65 with gantenerumab and placebo, respectively, in the GRADUATE I trial, and 2.82 and 3.01 in the GRADUATE II trial (difference, −0.31 and −0.19, respectively). The difference in the amyloid level on positron emission tomography (PET) between the gantenerumab group and the placebo group was −66.44 and −56.46 centiloids in the GRADUATE I and II trials, respectively, at week 116; 28.0 and 26.8 percent of the participants receiving gantenerumab in the two trials achieved amyloid-negative status. Participants receiving gantenerumab across both trials had lower cerebrospinal fluid levels of phosphorylated tau 181 and higher levels of amyloidβ42 than those receiving placebo; the two groups had similar accumulation of aggregated tau on PET.
"The use of the antiamyloid antibody gantenerumab did not lead to a slower decline in cognitive function than placebo," the authors write.
The study was funded by F. Hoffmann-La Roche, which manufactures gantenerumab.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Benefit of Thick Liquids in Alzheimer Disease and Dysphagia Unclear
MONDAY, May 6, 2024 -- For hospitalized patients with Alzheimer disease and related dementias (ADRD) and dysphagia, those receiving thick liquids are less likely to be intubated...
Differences ID'd in Tau Burden in Down Syndrome, Alzheimer Disease
THURSDAY, April 25, 2024 -- The spatial distribution, timing, and magnitude of tau burden differs for people with Down syndrome and those with autosomal-dominant Alzheimer...
Risk for Adverse Outcomes Increased With Antipsychotic Use in Dementia
FRIDAY, April 19, 2024 -- For adults with dementia, antipsychotic use is associated with increased risks for stroke, venous thromboembolism, myocardial infarction, heart failure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.